fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Baclofen

All products: general benefit

Lioresal · DIN 00455881 · 10 mg · tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2020-06-26 — choose a marketed DIN from the same-category list.Discontinued June 26, 2020 · checked October 5, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2020-06-26 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2020-06-26 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
Lioresal · DIN 00455881 Manufacturer: Novartis Pharma Canada Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 2020-06-26 · brand LIORESAL TAB 10MG · ATC M03BX01 BACLOFEN · form Tablet · route Oral · ingredients BACLOFEN 10 MG · company Novartis pharmaceuticals canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Ministry pays: $0.1595 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00455881)

Source record
DIN 00455881: Lioresal Raw flags: sec3=Y Item: 122000003; group id 240; item number 0430; lccId None; manufacturer id NOV Source form: Tab; strength: 10mg Recorded listing: General benefit Source prices (unrounded): $0.8795; ministry $0.1595 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00455881 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3182
Interchangeable products
Apo-Baclofen · DIN 02139332 · $0.1595 Baclofen · DIN 02287021 · $0.1595 Baclofen · DIN 02544660 · $0.1595 Jamp Baclofen · DIN 02544482 · $0.1595 Mylan-Baclofen · DIN 02088398 · $0.1595 PMS-Baclofen · DIN 02063735 · $0.1595 Ratio-Baclofen · DIN 02236507 · $0.1595
Shortage status: discontinued (June 26, 2020, reported by NOVARTIS PHARMACEUTICALS CANADA INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00455881
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since June 26, 2020 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (M03B, M03BX): coverage varies; not interchangeable

  • Cyclobenzaprine (Flexeril): not a benefit
  • Tizanidine (Zanaflex): not a benefit
  • Orphenadrine (Norflex): not a benefit
Other drugs in the same formulary class (12:20 Skeletal Muscle Relaxants) and how they are covered

Matched class: 12:20 Skeletal Muscle Relaxants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: DANTROLENE SODIUM 12:20 Skeletal Muscle Relaxants

CYCLOBENZAPRINE HCL

· 12 products · Listed, not a benefit · strengths: 10mg · Tab

TIZANIDINE HCL

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 4mg · Tab

ORPHENADRINE CITRATE

· 2 products · Listed, not a benefit · strengths: 60mg/2mL · Inj Sol-2mL Pk

DANTROLENE SODIUM

· 1 products · General benefit · strengths: 25mg · Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 12:20
Full class listing Related classes: 12:04 Parasympathomimetic (Cholinergic) Agents, 12:08 Parasympatholytic (Cholinergic Blocking) Agents, 12:12 Sympathomimetic (Adrenergic) Agents Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE pms-BACLOFEN (baclofen) is useful for the alleviation of signs and symptoms of spasticity resulting from multiple sclerosis. pms-BACLOFEN may also be of some value in patients with spinal cord injuries and other spinal cord diseases. https://pdf.hres.ca/dpd_pm/00059369.PDF PM date: December 11, 2020 Source product: PMS-BACLOFEN; DIN 02063735; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Lioresal · DIN 00455881 Shortage status: discontinued (2020-06-26, reported by NOVARTIS PHARMACEUTICALS CANADA INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00455881

Check this DIN again